Mount Sinai Medical Center, New York, NY Background: The relationship between the SYNTAX score (SS) and stent thrombosis (ST) has not been described. We therefore examined the relationship between SS and ST in high-risk patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) pts undergoing percutaneous coronary intervention (PCI). Methods: We stratified 2,627 pts from the ACUITY-PCI cohort by SS tertile distribution (in ACUITY: SS <7 (n¼854), SS 7-12 (n¼825), and SS >12 (n¼948); and from the original SYNTAX trial: SS<23 (n¼ 2315), SS 23-32 (n¼248), and SS >32 (n¼ 64)). Thirty-day and 1-year rates of ARC definite/probable ST were determined for each SS tertile. Results: A total 30 and 41 definite/probable STs occurred at 30 days and 1 year respectively. When stratified by ACUITY tertiles, 30-day and 1-year rates of definite/ probable ST were significantly greater in the highest tertile (SS>12, 2.0% and 2.8%) compared with the intermediate (SS7-12, 0.7% and 1.1%) and lowest tertiles (SS<12, 0.6% and 0.7%), p¼0.007 and p¼0.0009, respectively. When stratified by original SYNTAX tertiles, 30-day and 1-year rates of definite/probable ST were significantly greater in the highest (SS>32, 6.3% and 8.8%) and intermediate groups (SS23-32, 2.8% and 3.7%) compared with the lowest group (SS<22, 0.8% and 1.2%), p <0.0001 and p <0.0001, respectively. After multivariable adjustment for clinical differences between groups, SS (per 1 point increase) remained an independent predictor of both 30-day (hazard ratio [HR], 1.06; 95% confidence interval [CI] 1.03 to 1.09; p¼0.0002) and 1-year (HR, 1.06; 95% CI, 1.03 to1.09; p<0.0001) definite/ probable ST. Conclusions: In NSTE-ACS pts treated by PCI, the extent of severity of CAD, as assessed by the baseline SS, was strongly associated with the occurrence of ST both at 30 days and 1 year.
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Can in-stent neointimal characteristics predict late neointimal progression after drug-eluting stent implantation?: a serial optical coherence tomography study Bern University Hospital, Bern, Switzerland Background: Dual antiplatelet therapy (DAPT), consisting of aspirin plus a thienopyridine, is currently recommended for 6 to 12 months following drug-eluting stent implantation. We previously reported a low risk of stent thrombosis (ST) in the first year after ResoluteÔ Zotarolimus-eluting stent (R-ZES) placement among patients in whom DAPT was interrupted or discontinued beyond the first month post-procedure. We sought to examine the longer term impact of early DAPT discontinuation as well as the impact of later DAPT discontinuation on subsequent clinical outcomes. Methods: All patients with 3-year ST data (n¼4,896) treated with a R-ZES in the global RESOLUTE clinical program were analyzed according to DAPT status. ST was assessed based on the timing of first DAPT interruption (0-1, >1-12, >12-24 and >24-36 months), which was defined as an interruption of either aspirin or thienopyridine >14 days. Results: Baseline characteristics of all patients with a >14 day DAPT interruption included age 66 years, 32% with diabetes and 41% with an acute coronary syndrome. A total of 50 ST events occurred through 3 years after R-ZES; 29 (58%) of these events were within 1 month of stent placement regardless of DAPT status. The number (%) of events in each interruption period is shown in the figure.
Conclusions: For patients with a >14 day DAPT interruption after 1 month, the occurrence of subsequent ST remained low through 3 years following R-ZES implantation. These data underscore the necessity of additional prospective data in order to determine the optimal duration of DAPT after DES implantation. TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
